TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. ...

– Mr. Tamberrino and Profound's CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final preparations for the permanent CPT® Category 1 codes for TULSA going into effect at the beginning of 2025 – TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free ...

Profound Medical (PROF) shares rallied 5.1% in the last trading session to close at $7.85. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 17.2% loss over the past four weeks. The sudden surge in share price can be attributed to positive investor expectations from Profound's lead marketed product, the Tulsa-Pro system, which is approved for the ablation of prostate tissue. In July 2024, the U.S. Centers for M ...

TORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth "Big8" Conference on September 12, 2024 in New York City. The event will consist of one-on-one investor meetings. Due to the format of ...

Profound Medical Corporation (NASDAQ:PROF) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat - CEO Rashed Dewan - CFO Mathieu Burtnyk - COO Conference Call Participants Rick Wise - Stifel Ben Haynor - Lake Street Capital Markets Rahul Sarugaser - Raymond James Michael Sarcone - Jefferies Scott McAuley - Paradigm Capital Brian Gagno - Gagnon Securities Operator Welcome to the Profound Medical Second Quarter 2024 Financial Results conference call. ...

Profound Medical (PROF) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.31 per share when it actually produced a loss of $0.26, delivering a surprise of 16.13%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Profound Medical, which belongs to the ...

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Time: 4:30 p.m. ET About Profound Medical Corp. Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fib ...

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Date: Thursday, August 8, 2024 Live Call Registration: https://register.vevent.com/register/BIbfa8c9bee6c6463c8ca3a1937fbfd804 About Profound Medical Corp. Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide custo ...

Earlier this month, the company announced that the United States Centers for Medicare and Medicaid Services issued its proposed rules establishing, for the first time, a Category 1 CPT code for its lead-marketed product Tulsa-Pro system, approved for the ablation of prostate tissue effective Jan 1, 2025. This might have driven the share price rally. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation betw ...

According to the proposed rule, TULSA will have 3 physician codes to cover how therapy is delivered depending on if there are one or two physicians involved in the procedure: 5x006 TULSA Device Management and 5x007 TULSA Treatment, when two physicians are involved in the procedure, and 5x008 TULSA Complete Procedure, when performed by a single physician. TULSA will have a 0-day global period, indicating that the payment associated with the codes will only cover the work performed on the day TULSA is perform ...